drugset
drugset / Trial / NCT03761810

A Study of S6G5T3 in the Treatment of Acne Vulgaris

NCT03761810 ↗

Phase 3 Completed 434 enrolled Sol-Gel Technologies, Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the efficacy of S6G5T-3 compared to its vehicle when applied once daily for 12 weeks in participants with acne vulgaris.

Timeline

Start
2018-12-14
Primary completion
2019-10-23
Completion
2019-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject S6G5T-3 Unknown — Topical

Indications

acne